Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug duo outsmart EGFR-Mutant lung cancer?

NCT ID NCT01562028

Disease control Sponsor: ETOP IBCSG Partners Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial investigates whether combining two targeted drugs—erlotinib and bevacizumab—can help people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see if the combination extends the time before the cancer grows or spreads. Participants receive daily erlotinib pills and regular intravenous bevacizumab infusions, with researchers tracking progression-free survival and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
erlotinib and bevacizumab
What this could lead to
If successful, this combination could offer a new treatment option that delays cancer progression in people with EGFR-mutant lung cancer.
What could go wrong
This is a phase II trial, so results are preliminary. The combination may not improve outcomes and could cause side effects like bleeding, high blood pressure, or skin issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

109 people

The number who actually took part.

Start date

Jun 2012

Finished

Oct 2018

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * ECOG performance status 0-2 * Adequate haematological function, coagulation, liver function and renal function * Pathological diagnosis of predominantly non-squamous, non-small-cell lung cancer (NSCLC) * TNM version 7 stage IV disease including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease not amenable to curative treatment (including patients progressing after radiochemotherapy for stage III disease) * Measurable or evaluable disease (according to RECIST 1.1 criteria). * Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R) Exclusion Criteria: * Patients with increased risk of bleeding * Patients with clinically significant cardiovascular diseases * Patients with a history of thrombosis or thromboembolism in the 6 months prior to treatment * Patients with gastrointestinal problems * Patients with neurologic problems * Patients who have had in the past 5 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ breast carcinoma. * Patients with any known significant ophthalmologic anomaly of the ocular surface * Patients who received prior chemotherapy for metastatic disease * Patients who received previous treatment for lung cancer with drugs targeting EGFR or VEGF * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

Contacts and locations

Locations

  • AMCCH

    Tallaght, Ireland

  • Casa di Cura Maddalena

    Palermo, 90146, Italy

  • Centre Francois Baclesse

    Caen, 14000, France

  • Christie Hospital Manchester

    Manchester, M20 4BX, United Kingdom

  • Fondation du centre Pluridisciplinaire d'Oncologie (CePO)

    Lausanne, 1011, Switzerland

  • Geneva University Hospital

    Geneva, 1211, Switzerland

  • Hospital 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Clinico Universitario San Carlos

    Madrid, 28040, Spain

  • Hospital Clínic Barcelona

    Barcelona, 08036, Spain

  • Hospital De La Santa Creu I Sant Pau

    Barcelona, 08025, Spain

  • Hospital General Universitario Alicante

    Alicante, 03010, Spain

  • Hospital General de Valencia

    Valencia, 46014, Spain

  • Hospital Grosshansdorf

    Großhansdorf, 22927, Germany

  • Hospital La Fe

    Valencia, 46026, Spain

  • Hôpital de Marseille

    Marseille, 13915, France

  • ICO - Girona

    Girona, 17007, Spain

  • ICO - Hospital Duran i Reynals

    L'Hospitalet de Llobregat, 08907, Spain

  • ICO - Hospital Universitari Germans Trias i Pujol

    Badalona, 08916, Spain

  • Inselspital Bern

    Bern, 3010, Switzerland

  • Istituto Oncologica della Svizzera Italiana

    Bellinzona, 6650, Switzerland

  • Istituto Oncologico Veneto IRCCS

    Padova, 35128, Italy

  • Kantonsspital Luzern

    Lucerne, 6016, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, 9007, Switzerland

  • Kantonsspital Winterthur

    Winterthur, 8401, Switzerland

  • Kent Oncology Centre

    Maidstone, ME16 9QQ, United Kingdom

  • Lungenklinik Hemer

    Hemer, 58675, Germany

  • Mid Essex Hospital Services NHS Trust

    Chelmsford, Essex, CM1 7ET, United Kingdom

  • Mid-Western Regional Hospital

    Limerick, Ireland

  • Onkologiezentrum Berner Oberland

    Thun, 3600, Switzerland

  • Ospedale San Gerardo

    Monza, 20900, Italy

  • Papageorgias Hospital

    Thessaloniki, Greece

  • Policlinico Tor Vergata Roma

    Roma, 00133, Italy

  • Policlinico Umberto

    Roma, 00161, Italy

  • Queen's Hospital

    Burton-on-Trent, DE13 0RB, United Kingdom

  • Royal Marsden Hospital

    London, SW3 6JJ, United Kingdom

  • San Camillo Hospital

    Roma, 00151, Italy

  • St Vincent's University Hospital

    Dublin, Ireland

  • St. James's Hospital

    Dublin, Ireland

  • Thoraxklinik Heidelberg GmbH

    Heidelberg, 69126, Germany

  • University General Hospital of Heraklion

    Heraklion, Greece

  • University Hospital Basel

    Basel, 4031, Switzerland

  • University Hospital Galway

    Galway, Ireland

  • University Hospital Zurich

    Zurich, 8091, Switzerland

  • University Hospitals of Leicester

    Leicester, LE1 5WW, United Kingdom

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

  • Vall d'Hebron University Hospital

    Barcelona, 08035, Spain

  • Wrexham Maelor Hospital

    Wrexham, LL13 7TD, United Kingdom

  • Wythenshawe Hospital Manchester

    Manchester, M23 9LT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.